The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
Open accessAbstract
Coadministration with the human immunodeficiency virus (HIV) protease inhibitor ritonavir was investigated as a method for enhancing the levels of other peptidomimetic HIV protease inhibitors in plasma. In rat and human liver microsomes, ritonavir potently inhibited the cytochrome P450 (CYP)-mediated metabolism of saquinavir, indinavir, nelfinavir, and VX-478. The structural features of ritonavir responsible for CYP binding and inhibition were examined. Coadministration of other protease inhibitors with ritonavir in rats and dogs produced elevated and sustained plasma drug levels 8 to 12 h after a single dose. Drug exposure in rats was elevated by 8- to 46-fold. A > 50-fold enhancement of the concentrations of saquinavir in plasma was observed in humans following a single codose of ritonavir (600 mg) and saquinavir (200 mg). These results indicate that ritonavir can favorably alter the pharmacokinetic profiles of other protease inhibitors. Combination regimens of ritonavir and other protease inhibitors may thus play a role in the treatment of HIV infection. Because of potentially substantial drug level increases, however, such combinations require further investigation to establish safe regimens for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267
Self-citationHIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., & Ho, D. D. (1996) · Science · doi:10.1126/science.271.5255.1582 · Cited by 3,531
Self-citationViral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
Coffin, J. M. (1995) · Science · doi:10.1126/science.7824947 · Cited by 1,981
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., et al. (1995) · Nature · doi:10.1038/374569a0 · Cited by 974
Rational Design of Peptide-Based HIV Proteinase Inhibitors
Roberts, N. A., Martin, J. A., Kinchington, D., Broadhurst, A. V., Craig, J. C., Duncan, I. B., Galpin, S. A., Handa, B. K., Kay, J., Kröhn, A., et al. (1990) · Science · doi:10.1126/science.2183354 · Cited by 929
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Schipper, P. J., Mo, H.-M., Markowitz, M., Chernyavskiy, T., Niu, P., Lyons, N., et al. (1996) · Nature Medicine · doi:10.1038/nm0796-760 · Cited by 762
Self-citationDanner, S. A., Carr, A., Leonard, J. M., Lehman, L. M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332303 · Cited by 567
Self-citationKempf, D. J., Marsh, K. C., Denissen, J. F., McDonald, E., Vasavanonda, S., Flentge, C. A., Green, B. E., Fino, L., Park, C. H., & Kong, X. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2484 · Cited by 560
Self-citationKronbach, T., Fischer, V., & Meyer, U. A. (1988) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1988.87 · Cited by 533
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
Vacca, J. P., Dorsey, B. D., Schleif, W. A., Levin, R. B., McDaniel, S. L., Darke, P. L., Zugay, J., Quintero, J. C., Blahy, O. M., & Roth, E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4096 · Cited by 527
A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection
Markowitz, M., Saag, M., Powderly, W. G., Hurley, A. M., Hsu, A., Valdes, J. M., Henry, D., Sattler, F., Marca, A. L., Leonard, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332204 · Cited by 493
Self-citationOverview of patient compliance with medication dosing: a literature review.
Greenberg, R. N. (1984) · PubMed · Cited by 419
L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor
Dorsey, B. D., Levin, R. B., McDaniel, S. L., Vacca, J. P., Guare, J. P., Darke, P. L., Zugay, J. A., Emini, E. A., & Schleif, W. A. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00047a001 · Cited by 412
Kim, E. E., Baker, C. T., Dwyer, M. D., Murcko, M. A., Rao, B. G., Tung, R. D., & Navia, M. A. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00108a056 · Cited by 390
Kumar, G. N., Rodrigues, A. D., Buko, A. M., & Denissen, J. F. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12840-1 · Cited by 353
Self-citationThe Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients
Schapiro, J. M., Winters, M. A., Stewart, F., Efron, B., Norris, J., Kozal, M. J., & Merigan, T. C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-12-199606150-00003 · Cited by 296
A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
Stein, D. S., Fish, D. G., Bilello, J. A., Preston, S. L., Martineau, G. L., & Drusano, G. L. (1996) · AIDS · doi:10.1097/00002030-199605000-00006 · Cited by 172
Ketoconazole to Reduce the Need for Cyclosporine after Cardiac Transplantation
Keogh, A., Spratt, P., McCosker, C., Macdonald, P., Mundy, J., & Kaan, A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331004 · Cited by 161
P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer
Nedelcheva, V., & Gut, I. (1994) · Xenobiotica · doi:10.3109/00498259409038673 · Cited by 150
Kempf, D. J., Marsh, K. C., Paul, D. A., Knigge, M. F., Norbeck, D. W., Kohlbrenner, W. E., Fino, L. C., Vasavanonda, S., Bryant, P., & Wang, X. C. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.11.2209 · Cited by 134
Self-citationVincent, S. H., Karanam, B. V., Painter, S. K., & Chiu, S. L. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90711-5 · Cited by 105
Rodrigues, A. D., Mulford, D. J., Lee, R. D., Surber, B. W., Kukulka, M. J., Ferrero, J. L., Thomas, S. B., Shet, M. S., & Estabrook, R. W. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06655-3 · Cited by 75
Self-citationITERATIVE PROTEIN STRUCTURE-BASED DRUG DESIGN AND SYNTHESIS OF HIV PROTEASE INHIBITORS
Kalish, V. J., Kaldor, S. W., Shetty, B. V., Tatlock, J. H., Davies, J. F., Hammond, M., Dressman, B. A., Fritz, J. S., Appelt, K., Reich, S., et al. (1995) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(23)00125-3 · Cited by 23
Cited by
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Choy, K.-T., Wong, A. Y.-L., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., Chu, D. K. W., Chan, M. C. W., Cheung, P. P.-H., Huang, X., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104786 · Cited by 922
Protease Inhibitors: Current Status and Future Prospects
Leung, D., Abbenante, G., & Fairlie, D. P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990412m · Cited by 883
HIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Metadata
- Authors
- Kempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., Sun, E., Pizzuti, D., Plattner, J. J., Norbeck, D. W., & Leonard, J. M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-03
- Volume
- 41
- Issue
- 3
- Pages
- 654-660
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2109604183
- Cited by
- 417
- References
- 24
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.